This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Anari F , O'Neill J , Choi W , Chen DYT , Haseebuddin M , Kutikov A , Dulaimi E , Alpaugh RK , Devarajan K , Greenberg RE , Bilusic M , Wong YN , Viterbo R , Hoffman-Censits JH , Lallas CD , Trabulsi EJ , Smaldone M , Geynisman DM , Zibelman M , Lin J , Kelly WK , Uzzo R , McConkey D , Plimack ER
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial
Eur Urol Oncol. 2018 May;1(1) :54-60
PMID: 30420974 PMCID: PMC6226048
AbstractBackground: Accelerated (also termed dose-dense, DD) chemotherapy regimens such as accelerated methotrexate, vinblastine, doxorubicin, and cisplatin have shown better efficacy and tolerability in the metastatic setting, and shortened the time to surgery in the neoadjuvant setting compared to standard-schedule regimens. We hypothesized that a DD schedule of gemcitabine and cisplatin (GC) would shorten the time to surgery and yield similar pathologic complete response rates (pT0) in patients with muscle-invasive bladder cancer (MIBC) compared with historical controls with standard GC. Objective: To determine the safety and efficacy of neoadjuvant DDGC in MIBC. Design setting and participants: Patients with cT2-4a, N0-1, M0 MIBC were eligible and received three 14-d cycles of DDGC with pegfilgrastim support followed by radical cystectomy with lymph node dissection. The primary end point was the pT0 rate. Molecular subtypes were assigned and correlated with survival. Results and limitations: Thirty-one patients were evaluable for toxicity and response, of whom 58% had baseline clinical stage >T2N0M0; the median age was 69 yr. Ten patients (32%, 95% confidence interval [CI] 16-49%) achieved ypT0N0 status at cystectomy. Another four patients (13%, 95% CI 1-25%) were downstaged to non-muscle-invasive (<pT2N0) disease. Most patients (54.8%) experienced only grade 1-2 treatment-related toxicities. However, seven patients (23%) had clinically significant vascular events, leading to early closure of the study. Thirty patients (94%) underwent cystectomy. The median time from the start of chemotherapy to cystectomy was 9.3 wk. There was no correlation between molecular subtypes and survival. Conclusions: DDGC yielded a similar pT0 rate to that noted retrospectively with standard GC. Vascular events precluded, delayed, or increased the risk of surgery for 23% of patients, resulting in early closure of the study. Additional prospective studies with embedded biomarker correlatives of GC in the neoadjuvant setting are critical to accurately define both the activity and toxicity of this combination in MIBC. Patient summary: Neoadjuvant chemotherapy before cystectomy is the standard of care for muscle-invasive bladder cancer (MIBC). This prospective phase 2 study tested a dose-dense schedule of gemcitabine and cisplatin in MIBC. The study was closed early because of a higher than expected rate of vascular events. These data suggest that caution is required in using this regimen, particularly when there is better prospective evidence for the safety and efficacy of alternative regimens such as dose-dense or accelerated methotrexate, vinblastine, doxorubicin, and cisplatin.
Notes2588-9311 Anari, Fern O'Neill, John Choi, Woonyoung Chen, David Y T Haseebuddin, Mohammed Kutikov, Alexander Dulaimi, Essel Alpaugh, R Katherine Devarajan, Karthik Greenberg, Richard E Bilusic, Marijo Wong, Yu-Ning Viterbo, Rosalia Hoffman-Censits, Jean H Lallas, Costas D Trabulsi, Edouard J Smaldone, Marc Geynisman, Daniel M Zibelman, Matthew Lin, Jianqing Kelly, W Kevin Uzzo, Robert McConkey, David Plimack, Elizabeth R P30 CA006927/CA/NCI NIH HHS/United States Journal Article Netherlands Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 6.